Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

被引：14
|
作者：
Foran, James M. [1 ]
DiNardo, Courtney D. [2 ]
Watts, Justin M. [3 ]
Stein, Eytan M. [4 ]
De Botton, Stephane [5 ]
Fathi, Amir T. [6 ]
Prince, Gabrielle T. [7 ]
Stein, Anthony [8 ]
Stone, Richard M. [9 ]
Patel, Prapti A. [10 ]
Tallman, Martin S. [4 ]
Choe, Sung [11 ]
Wang, Hongfang [11 ]
Zhang, Vickie [11 ]
Fan, Bin [11 ]
Yen, Katharine E. [11 ]
Oluyadi, Abdulafeez [11 ]
Winkler, Thomas [11 ]
Hickman, Denice [11 ]
Agresta, Samuel V. [11 ]
Liu, Hua [11 ]
Wu, Bin [11 ]
Attar, Eyal C. [11 ]
Kantarjian, Hagop M. [2 ]
机构：
[1] Mayo Clin Florida, Jacksonville, FL USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Inst Gustave Roussy, Villejuif, France
[6] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[7] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[11] Agios Pharmaceut Inc, Cambridge, MA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123946
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4254
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model
    Yen, Katharine
    Chopra, Vivek S.
    Tobin, Erica
    Avanzino, Brian
    Mavrommatis, Konstantinos
    DiMartino, Jorge
    MacBeth, Kyle J.
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
    Choe, Sung
    Wang, Hongfang
    DiNardo, Courtney D.
    Stein, Eytan M.
    De Botton, Stephane
    Fathi, Amir T.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Stone, Richard M.
    Quek, Lynn
    Konteatis, Zenon
    Dang, Lenny
    Zhang, Vickie
    Liu, Hua
    Attar, Eyal C.
    Wu, Bin
    BLOOD, 2019, 134
  • [33] Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
    Chandhok, Namrata S.
    Wei, Wei
    Halene, Stephanie
    Prebet, Thomas
    BLOOD, 2019, 134
  • [34] Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
    Pollyea, D. A.
    de Botton, S.
    Fathi, A. T.
    Stein, E. M.
    Tallman, M. S.
    Agresta, S.
    Bowden, C.
    Fan, B.
    Prah, M.
    Yang, H.
    Yen, K.
    Stone, R. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 195 - 195
  • [35] Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).
    Dinardo, Courtney Denton
    Stein, Eytan
    Pigneux, Arnaud
    Altman, Jessica K.
    Collins, Robert
    Erba, Harry Paul
    Watts, Justin M.
    Uy, Geoffrey L.
    Kapsalis, Stephanie M.
    Liu, Hua
    Winkler, Thomas
    Roboz, Gail J.
    de Botton, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
    DiNardo, Courtney D.
    Stein, Eytan M.
    Pigneux, Arnaud
    Altman, Jessica K.
    Collins, Robert
    Erba, Harry P.
    Watts, Justin M.
    Uy, Geoffrey L.
    Winkler, Thomas
    Wang, Hongfang
    Choe, Sung
    Liu, Hua
    Wu, Bin
    Kapsalis, Stephanie M.
    Roboz, Gail J.
    de Botton, Stephane
    LEUKEMIA, 2021, 35 (11) : 3278 - 3281
  • [37] Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
    Courtney D. DiNardo
    Eytan M. Stein
    Arnaud Pigneux
    Jessica K. Altman
    Robert Collins
    Harry P. Erba
    Justin M. Watts
    Geoffrey L. Uy
    Thomas Winkler
    Hongfang Wang
    Sung Choe
    Hua Liu
    Bin Wu
    Stephanie M. Kapsalis
    Gail J. Roboz
    Stéphane de Botton
    Leukemia, 2021, 35 : 3278 - 3281
  • [38] Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.
    Fan, Bin
    Mellinghoff, Ingo K.
    Wen, Patrick Y.
    Pandya, Shuchi Sumant
    Jiang, Liewen
    Liu, Guowen
    Nimkar, Tara
    Yang, Hua
    Dai, David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] AG-120 (ivosidenib), a first in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma
    Ishii, Yuko
    Sigel, Carlie
    Lowery, Maeve A.
    Goyal, Lipika
    Gliser, Camelia
    Jiang, Liewen
    Pandya, Susan
    Bin Wu
    Choe, Sung
    Deshpande, Vikram
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [40] ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY
    Stein, E. M.
    DiNardo, C. D.
    Pollyea, D. A.
    Fathi, A. T.
    Roboz, G. J.
    Altman, J. K.
    Stone, R. M.
    Flinn, I. W.
    Kantarjian, H. M.
    Collins, R.
    Patel, M. R.
    Stein, A.
    Sekeres, M. A.
    Swords, R. T.
    Medeiros, B. C.
    Knight, R. D.
    Agresta, S.
    de Botton, S.
    Tallman, M. S.
    HAEMATOLOGICA, 2017, 102 : 175 - 175
12345